Alyeska Investment Group
ARTV

Alyeska Investment Group’s Artiva Biotherapeutics ARTV Stock Holding History

Alyeska Investment Group’s Portfolio ARTV Stock Details ARTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.65M Buy
273,615
+173,615
+174% +$1.58M 0.01% 551
2026
Q1 		$644K Hold
100,000
– – ﹤0.01% 586
2025
Q4 		$429K Hold
100,000
– – ﹤0.01% 565
2025
Q3 		$287K Hold
100,000
– – ﹤0.01% 570
2025
Q2 		$151K Hold
100,000
– – ﹤0.01% 540
2025
Q1 		$300K Hold
100,000
– – ﹤0.01% 483
2024
Q4 		$1.01M Hold
100,000
– – ﹤0.01% 496
2024
Q3 		$1.54M Buy
+100,000
New +$1.16M 0.01% 437

Other funds holding ARTV

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Alyeska Investment Group's ARTV Position: Q2 2026 in Review

Alyeska Investment Group increased its Artiva Biotherapeutics (ARTV) stake by 174% in Q2 2026, buying an estimated $1.58M and bringing the position to 273,615 shares worth $2.65M. The position accounts for 0.01% of the portfolio, ranked #551.

Alyeska Investment Group first reported a position in ARTV in Q3 2024 and has held it in 8 quarters since. 72 funds tracked by Wall St. Rank hold ARTV as of Q2 2026.

  • Alyeska Investment Group held 273,615 shares of Artiva Biotherapeutics worth $2.65M as of Q2 2026.
  • Alyeska Investment Group bought 173,615 Artiva Biotherapeutics shares in Q2 2026, an estimated $1.58M.
  • Artiva Biotherapeutics made up 0.01% of Alyeska Investment Group's portfolio in Q2 2026, its #551 holding.
  • Alyeska Investment Group first reported a position in Artiva Biotherapeutics in Q3 2024 and has held it in 8 quarters since.
  • 72 funds tracked by Wall St. Rank held Artiva Biotherapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.